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doi:10.1016/j.pedneo.2011.11.006Introduction: Recently, many international studies have suggested that pediatric patients
from diverse ethnic origins confront unique challenges for transplantation. Data concerning
the efficacy and safety of transplantation for various pediatric renal transplant populations
remains limited and are often confounded by immunosuppressive protocols. In one study,
we aimed to evaluate the short- and long-term outcomes of renal transplants in Jordanian
children in comparison with groups of different nationalities.
Methods: We retrospectively retrieved data for 34 Jordanian children who received kidney
transplants from living donors between January 2003 and January 2009. Subsequently, we
continued to follow-up with these selected patients at scheduled clinic visits to prospectively
collect long-term data for a period of approximately 22 months 15 months.
Results: The patients included in this study ranged between 4 years and 19 years of age. The
male/female ratio was 0.79. Glumerulonephritis (35.3%) was the most common cause of
end-stage renal disease in the sample of this study; 23.5% had received a preemptive trans-
plant. All patients also received triple immunosuppressive therapy, consisting of tacrolimus
(TAC), prednisolone, and mycophenolate mofetil (nZ 26) or azathioprine (nZ 8). Further-
more, the rate of acute rejection episodes was lower in the sample of this study than the
average rate of many previous studies. The patients’ survival rate at 1 year, 2 years and 3 years
posttransplant was nearly 100%. The corresponding graft survivals were 97.1%, 94.12% and
91.2% respectively. Beyond three years, one female patient died postgraft loss. This graft loss
was mainly attributed to recurrent glomerulonephritis. Strikingly, the prevalence of posttrans-
plant diabetes (PTD) and hypertension was higher than reported international figures. Other
adverse events, such as infections, were manageable.rofessor of Clinical Pharmacy, Derprtment of Clinical Pharmacy, Princess Nora University, Riyadh
com (S. Shilbayeh).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Pediatric renal transplantation in Jordan 25Conclusion: The average result of pediatric renal transplantation in Jordan is more successful
than the average results of this procedure in many developed countries, especially in terms of
early graft function, acute rejection episodes as well as long-term patient and graft survivals.
However, additional studies are needed to better characterize pharmacokinetic of TAC and to
fully understand those factors that lead to an increased probability of developing conditions
like PTD and hypertension.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
There have been several clinical trials,1e4 retrospective5e19
and prospective20e30 long-term follow-up studies, con-
ducted to study the outcomes of renal transplants for
recipients who receive various immunosuppressive regi-
mens. Unfortunately, efficacy and safety parameters
remain scarce in the pediatric population literature.31
Although a meta-analysis study has been conducted, the
best choice calcineurin inhibitor and the best outcome
measure for long-term graft survival are still unresolved
issues.32 Moreover, recent international studies have sug-
gested that adults and pediatric patients of diverse ethnic
or racial origins confront different challenges to successful
transplantation2e4,11,16e19,30,33e35 (Table 1). Investigators
have provided various possible explanations and multifac-
torial interplay, including genetic, environmental, immu-
nologic and socioeconomic factors, as well as the variability
in prevalence patterns for the etiologies of end-stage
renal disease (ESRD) among different populations. In
particular, some studies have previously linked socioeco-
nomic criteria, such as low income, a lack of education,
a lack of insurance, and noncompliance with immunosup-
pression therapy, with a significantly adverse contribution
to allograft survival rates in certain ethnic minorities.33,36,37
By contrast, multivariate analysis reports33 have revealed
that socioeconomic factors did not account for these
differential outcomes. This conclusion has led some
authors to postulate that there may be a higher potential
for the association of negative survival rates with physio-
logic discrepancy, such as a greater prevalence of serious
ESRD causes38e40 (particularly focal glumerulosclerosis)
or a higher incidence of cardiovascular risk factors33,34
(mainly diabetes, hypertension, and hypercholesterol-
emia) in Asians and African-Americans as compared with
Caucasians. Therefore, the real impact of ethnicity and
racial disparities on clinical outcomes following kidney
transplantation remains a subject of considerable debate.
Although the outcome data reviewed in Table 1 are
controversial, extrapolation of any of the observed conclu-
sions to the context of the Jordanian population is difficult
because previously collected data were obtained by
different study designs that included various ethnic/racial
groups, heterogeneous ESRD etiologies, or dissimilar age
categories. Also, previously collected data have often rep-
resented the experience of one institution in one country.
This manuscript describes the details of the first Jorda-
nian study of a sample of pediatric patients who previously
received a renal transplant.2. Patients and Methods
Pediatric renal transplants started in our center (Royal
Medical Services, King Hussain Medical Center, Pediatric
Department, Jordan) in 2003. By 2009, 40 children had
received a living donor kidney graft at this center. Four
patients died shortly after the operation. These deaths
were attributed to vascular thrombosis, recurrence of old
disease, or surgical complications. In addition, two patients
died in the follow-up period. After obtaining approval from
a local ethics committee, this study was initiated in January
2007. We retrospectively retrieved the data from charts/
medical records of all patients who received a kidney
transplant from living donors between January 2003 and
January 2009. Subsequently, we continued to follow-up in
monitoring the patients at each of their scheduled clinic
visits to prospectively collect long-term data for an average
of 22 months 15 months.
A comprehensive data-collection form was designed for
the purpose of this study. This form collected information
on patients’ demographics, anthropometry, pre- and post-
transplant medications (such as antihypertensives, insulin,
iron, calcium and vitamin supplements, etc.), etiology of
ESRD, dialysis modality (peritoneal dialysis, hemodialysis,
or none), date and age of transplant, donor source, recip-
ient baseline medical, and laboratory evaluations. The
primary follow-up endpoints included the incidence of
acute or chronic rejection, nephrotoxicity, and patient and
graft survival. Acute rejection in this study only included
biopsy proven episodes, which were defined as a rapid and
unexplained rise in serum creatinine (SrCr) of at least
0.3 mg/dL/day above the considered baseline posttrans-
plant; the use of high-dose steroid therapy or antibody
treatment was clearly associated with subsequent
improvement of renal function. If signs and symptoms
remained unresolved after “pulse” corticosteroid (methyl-
prednisolone of 500 mg intravenous infusion over 2 hours
for 3- to 5-day period), subsequent therapy was based on
the severity of rejection with antithymocite globulin (ATG)
being reserved to treat the most severe rejections.
Although drug-induced nephrotoxicity was confirmed in
the presence of high tacrolimus (TAC) whole blood
concentrations with other typically associated clinical
manifestations including raised SrCr (> 0.15 mg/dL/day)
and blood urea nitrogen (BUN) levels, hyperkalemia,
hyperuricemia, and decreased fractional excretion of
sodium, this was promptly resolved after TAC dose reduc-
tion. Chronic rejection was confirmed based on histological
findings for renal core biopsy. Graft loss was defined as
Table 1 Comparisons of major renal transplant outcomes among various ethnic/ racial groups (literature review).
Author (date) PoP Study
design
Ethnic or Racial
group
Outcomes (%)
1year PS 5 years PS 1year GS 5 years GS AR DGF CR PTD PTH
Neylan et al (1998)4 A CT African-American
Caucasian
94.6 NS
94.7
d 91.1 NS
90.4
d 23.2 NS
29.8
50 NS
45.6
d 36.6*
12.2
57.1*
49.1
Hauser et al (1998)3 A CT Caucasian 92.5 d 82 d 23.5 d d d d
Trompeter et al (2002)2 P CT Caucasian 97 d 90.3 d 36.9 23.3 d 3 68.9
Loucaidou et al (2004)17 A R Indo-Asian
Non- Indo-Asian
d 70NS
83
d NS NS d d d d
Pallet et al (2005)33 A Pr African European
Caucasian
98NS
97
93NS
92
92NS
92
83NS
83
31NS
30
44*
30
d d d
Dooldeniya et al (2006)34 A Pr Indo-Asian
Caucasian
d NS d NS 39.1NS
53.3
30.4NS
36.7
d 10.9*
3.3
NS
Weber et al (2006)18 A R Canadian
Aboriginal
Caucasian
d 50*
75
d 66NS/26 *
,y
67/47
NS 30NS
24
d 16*
8
d
Omoloja et al (2007)19 P R African-American
Caucasian
d d d 59.9*
77.7
d d d d d
Vasudevan et al (2008)11 P R Indo 100 94 94 82 18 21.2 18.2 d 75
OPTN-SRTR (2008)30 A / P Pr Black
White
Asian
Hispanic/ Latino
84.9*
80.6
95.7
90.1
d 94.6NS
95.7
97.4
96.2
71.8 /43.7*
,y
81.7 /59.6
89 /65.1
84.6 /64
d d d d d
Hau Shu et al (2008)16 P R Chinese 100 92.1 /71.4y 98.4 88.9 /68.3y 30.2 d d 4.8 41.3
Matsuda-Abedini et al (2009)36 P R British Columbia
Aboriginal
Non-Aboriginal
d 87.5*
95.6
d d 33.3 NS
39.3
0.04NS
0.007
50*
26.7
d d
Oztek et al (2009)35 P R Austria
Immigrant
Native
100 NS
97.2
100 NS
93.7
88.2 NS
92.9
88.2 NS
86.1
20 NS
37
d d d d
PoP, population; A, adults; P, pediatrics; CT, clinical trial; Pr, prospective follow-up; R, retrospective analysis; PS, Patient Survival; GS, Graft Survival; AR, acute rejection in 1st year; DGF,
delayed graft function; CR; chronic rejection; PTD, post-transplant diabetes; PTH, post-transplant hypertension; NS; no statistically significant difference.
* statistically significant.
y 10-years data.
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Table 2 Demographic and baseline clinical characteristics
of renal transplanted pediatrics.
Variables
Number of patients 34
Age (yrs) at time of transplantation
(mean SD)
11.3 2.9
< 13 years 21 (35.6)
 13 years 13 (22)
Gender
Male, n (%) 15 (44.1)
Female, n (%) 19 (55.9)
Weight (kg) at time of transplantation
(mean SD)
29.7 10
Height (cm) at time of transplantation
(mean SD)
128.6 15.6
Donor, n (%)
Father 11 (32.4)
Mother 16 (47.1)
Brother 1 (2.9)
First degree relative 2 (5.9)
Living unrelated 4 (11.8)
Modality of dialysis, n (%)
HD 21 (61.8)
PD 3 (8.8)
HD and PD 2 (5.9)
Duration of dialysis, months (mean, range)
HD 15.7 3.5
PD 21 7.9
HD and PD 20 4
Pre emptive transplant, n (%) 8 (23.5)
Primary reason for transplant, n (%)
Congenital hypodysplasia of the kidney 11 (32.4)
Hereditary nephritis 5 (14.7)
Reflux nephropathy 6 (17.6)
Glumerulonephritis 12 (35.3)
Pre-transplant hypertention, n (%) 28 (47.5)
SBP (mmHg) 119 20.5
DBP (mmHg) 78.8 15.3
GFR prior transplantation (mL/ min/
1.73 m2, mean SD)
14.9 10.4
Pre-transplant clinical laboratory (mean SD)
Serum creatinine (mg/dL) 6.4 2.8
Serum potassium (meq/ L) 4.7 1.3
BUN (mg/ dL) 72.5 42.9
Glucose (mg/ dL) 138.8 174.6
Hemoglobin (g/ dL) 8.6 1.8
Hematocrit (%) 25.9 5.7
Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; GFR,
glomerular filteration rate; BUN, blood urea nitrogen.
Pediatric renal transplantation in Jordan 27a condition in which any other modality of renal replace-
ment therapy is required.
Safety was assessed based on the described adverse
events and routine laboratory evaluations, including Full
Chemistry and Hematology tests. In addition, vital signs,
body weight, and height were continuously recorded.
Glomerular filtration rate (GFR) was estimated based on
Schwartz’s formula41:
GFR (mL/min/1.73 m2)Z K height (cm)/SrCr (mg/dL),
where K factor was 0.55 for all children (boys and girls)
aged 2 to 12 years and girls 13 to 21 years, whereas it was
0.7 for boys ranging from 13 to 21 years of age.
3. Immunosuppressive Regimens
The standard immunosuppressive protocol for pediatric
renal transplant at our center considered TAC, rather than
cyclosporine, as the primary calcineurin inhibitor due to
findings that suggest its superior efficacy and comparable
safety profiles in various pediatric populations.1,3,4 The
initial TAC dose was to be administered within 24 hours of
transplantation. Its recommended dosage was 0.3 mg/kg/
day to achieve trough concentrations of between 10 ng/mL
and 20 ng/mL during the first month after transplantation,
and 0.1 mg/kg/day thereafter to achieve trough levels of
between 5 ng/mL and 10 ng/mL. Steroids were adminis-
tered preoperatively in an intravenous dose of 300 mg/m2,
and then orally, tapering from 60 mg/m2 per day to
15 mg/m2 every other day within 3 months. Mycophenolate
mofetil (MMF) or azothioprine were also combined with any
previous therapy at a dose of 600 mg/m2 per day and
between 50 mg/day and 100 mg/day, respectively.
TAC whole blood trough concentrations were monitored
throughout the follow-up visits and the assay was per-
formed using a microparticle enzyme immunoassay (Abbott
IMx, Abbott Laboratories, Abbott Park, IL, USA).
4. Statistical Analysis
All of the collected data were coded, entered and analyzed
using SPSSª software (version 17.0; SPSS Inc, Chicago, IL,
USA). The data were generally analyzed and expressed as
the mean standard deviation for continuous variables and
as the percentage of the population for categorical
variables.
A student t test and analysis of variance test (with
Tukey’s post-hoc test) were employed for paired and
multiple comparisons of renal function measurements, TAC
serum levels, dosage requirements at different points in
time using the GraphPad Prism version 5.02 for Windows
(GraphPad Software, San Diego, CA, USA), respectively. A
p value <0.05 was considered to indicate statistical
significance.
5. Results
A total of 34 pediatric renal transplant recipients at our
center (between 2003 and 2009) were included in this
cohort study. They all received transplants from living
donors. The baseline demographic and clinical profilecriteria are summarized in Table 2. The sample patients’
ages ranged between 4 years and 19 years of age. The
male/female ratio was 0.79. Six patients (3 males, 3
females) were below 9 years of age at the time of trans-
plantation. Glumerulonephritis (35.3%) was the most
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Figure 1 Mean Tac whole blood trough levels during follow-
up post renal transplantation.
28 S. Shilbayeh, I. Hazzacommon cause of ESRD in our population, followed by
congenital hypodysplasia (32.4%). Focal segmental glo-
merulosclerosis (FSGS, nZ 5), membranoprofilerative
glumerulonephritis (MPGN, nZ 6), and hemolytic uremic
syndrome (nZ 1) were the main etiologies among glu-
merular diseases prevalent in our cases.
5.1. Immunosuppressive therapy
All 34 patients received triple immunosuppressive therapy
(Table 3), which consisted of TAC and prednisolone, MMF
(nZ 26) or azathioprine (AZA; nZ 8). However, MMF was
substituted with AZA in five cases, and MMF replaced AZA in
another four cases due to intolerable adverse events
encountered within the first year.
Initially, the mean daily dose of TAC (mg) on the 1st day
(initial dosing), 7th day, 14th day, 1 month, 1.5 months, 2
months, 3 months, 6 months, 9 months, and 12 months
were respectively as follows: 7.2 2.2, 7.4 2.3, 7.3 2.3,
7.3 2.8, 7.1 2.9, 6.6 2.6, 6.6 2.4, 6.1 2.1, 6.1
2.1, and 6.1 2.2.
The maximum mean for the total daily doses of TAC
required to achieve target blood concentrations (10e20 ng/
mL) was discerned during the first month of therapy,
and gradually in the subsequent follow-up period with
the lowest mean dose requirements to attain target
concentration (5 ng/mL) observed at a 3-year interval
(5.7 1.5 mg/day). Figure 1 depicts the mean trough
concentrations of TAC during the follow-up period.
The mean daily steroid dosage decreased from 19.6 mg/
day in the first month to 5.2 mg/day in the twelfth month.
All patients continued to take steroids at a low dose
throughout the study observation period.
5.2. Patient and graft survival
The patients’ survival rate at 1 year, 2 years, and 3 years
was 100%. Beyond 3 years, one female patient died post-
graft loss after reinstituting hemodialysis 5 months before
her death. Her death was attributed to further complica-
tions with the subsequent development of diabetes, cyto-
megalovirus (CMV) and Candida infections.Table 3 Immunosuppressive therapy.
Drug Dose (mg/ day)*
(mean SD)
Range
(mg/ day)
N, (%)
TAC 7.2 2.2 3-14 34 (100)
Prednisolone 40.9 16.1 5-60 34 (100)
MMF 883 284.2 500-1500 30 (88.2)
AZA 75 21.9 50-100 13 (38.2)
TACþMMFþ steroids 26 (44.1)
TACþ AZAþ steroids 8 (13.6)
Substituted
MMF with AZA
5 (14.7)
Substituted
AZA with MMF
4 (11.8)
TAC, tacrolimus; MMF, mycophenolate mofetil; AZA, azathioprine.
* initial starting dose.The graft survivals at 1 year, 3 years, and 4 years were
97.1%, 94.12%, and 91.2% respectively. In total, three grafts
were lost due to a poorly functioning graft subsequent to
acute tubular necrosis (ATN), recurrent Mesangiocapillary
glomerulonephritis (MCGN) and chronic rejection, respec-
tively. However, the first two cases remained on hemodi-
alysis for the rest of the study period. The chronic rejection
case died 6 months later.
5.3. Acute rejection
During the first year, five acute rejection episodes were
experienced in five patients (14.7%). Only one of the
episodes occurred in a child who had received a preemptive
transplant. Two episodes were encountered on the second
posttransplant day due to severe renal artery stenosis and
ATN secondary to recurrent MPGN. Although one of the
acute rejections occurred on 24th day, that patient’s renal
biopsy revealed vascular rejection associated with recur-
rence of FSGS. In the 4th month, another patient experi-
enced acute rejection due to acute renal failure secondary
to ureteral obstruction; this condition was managed by
inserting a double-J catheter while inducing intensive
steroid therapy. The final acute rejection was reported in
the 11th month but the etiology was unknown. The average
TAC trough level before rejection was 5.93 ng/mL 0.8 ng/
mL, which was considered below the optimal target,
particularly in the period of the initial two episodes.
Four of the previous episodes were treated with pulses
of methylprednisolone of 500 mg intravenous infusion over
2 hours for 3 to 5 days with or without ultrafilteration,
followed by the tapering of steroids. However, ATG was
required to be initiated at a dose of 200 mg for 5 days in one
corticosteroid-resistant ATN case which was partially
responsive.
5.4. Chronic rejection
During the follow-up, five patients (14.7%) displayed
a progressive irreversible rise in SrCr above 2.5 mg/dL, and
thereafter progressed to chronic allograft nephropathy.
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Figure 2 Mean GFR ( SD) during follow-up post renal
transplantation according to age groups.
Pediatric renal transplantation in Jordan 29One case was treated with ATG but remained unre-
solved. Three patients developed chronic rejection and lost
their grafts, subsequently returning to dialysis.
5.5. Renal function
As markers for renal function, SrCr and BUN concentrations
were measured routinely in each scheduled clinic visit and
throughout the follow-up study period. The mean values for
renal function parameters at different time points are
shown in Table 4.
At one year posttransplant, SrCr was normal in 21
patients (35.6%), five patients (8.5%) had SrCr levels
between 1 mg/dL and 1.39 mg/dL, six patients had SrCr
levels between 1.4 mg/dL and 2 mg/dL and only 6% were
higher than 2 mg/dL. In regard to BUN, 22 (37.3%) patients
had levels below 20 mg/dL, nine patients had levels
between 20 mg/dL and 44 mg/dL and only 3 (8.8%) had
elevated urea levels (> 44 mg/dL). In regard to GFR, no
significant difference was found between younger (< 13
years old) and older children ( 13 years) in our population
at any given time (Figure 2). The maximum improvement in
GFR was observed at Day 14 posttransplant, and it was
maintained with minimal changes throughout the initial 18
months. Although the mean GFR at Month 24 (73.6 26.6)
and Month 36 (80 16.3) further declined compared with
previous measurements, particularly in the first year, these
deteriorations did not reach statistical significance
(p> 0.05, ANOVA test).
5.6. Adverse events
The incidence of adverse events is summarized in Table 5. A
total of 28 (82.4%) patients experienced at least one
adverse event during the first year posttransplant. Of the
adverse events, 42 (60%) required hospitalization and
management for a period ranging between 2 days and 30
days. Other adverse events were sometimes managed by
drug therapy on an outpatient basis (28.5%), or no action
was required to be taken (12.9%). The most frequently re-
ported adverse events were urinary tract infection, hyper-
kalemia, and respiratory infections. CMV was confirmed in
three patients who were successfully treated with acyclovir
or gancyclovir. Diarrhea occurred in five patients, and their
conditions improved after discontinuation, dose reduction
or withhold of MMF for one week.
New-onset insulin-dependent diabetes mellitus, defined
as insulin use for  30 consecutive days in previouslyTable 4 Serum creatinine, BUN, and estimated graft function o
Time after transplantation* Serum creatinine (mg/dL)
Month 3 0.84 0.33
Month 6 0.84 0.3
Month 9 0.94 0.3
Month 12 1.15 1.51
Month 24 1.2 0.9
Month 36 1.03 0.3
*P> 0.05; statistical significance of mean difference between repeate
Tukey’s test. Abbreviations: BUN, blood urea nitrogen; GFR, glomerunondiabetic patients, was reported for four patients (11.8%)
who continued to use insulin until the end of the observa-
tion period. Newly diagnosed hypertension requiring two
or more antihypertensive medications was encountered in
two patients (5.9%). Nephrotoxicity was reported in four
patients, which was associated with elevated TAC trough
concentrations (mean, 19.9; range, 15e24.4 ng/mL) and
raised SrCr (>3 mg/dL).6. Discussion
In the present cohort, we recall a previous national survey
which had expressed a lower prevalence of pediatric ESRD
in Jordan (14.5 per million children less than 14 years of
age) as compared with similar European and American
reports.42 Yet the registered mortality rate among our ESRD
series at that time was 52.2%. This figure was considered to
be very high in comparison with an average mortality rate
of 7% as reported in the USA.43 This high mortality rate is
attributed to various causes but mostly due to the delay in
diagnosis and hence commencement of dialysis modality, as
well as the relatively recent incorporation of a pediatric
renal transplantation program in Jordanian healthcare
services (mainly in 2003), as compared with the earlier
foundation of such programs in many developed countries.
Herein, we describe the cumulative Jordanian experiencen as calculated by Schwartz formula after transplantation.
BUN (mg/dL) GFR (mL/ min/ 1.73 m2)
19 8.2 96.76 27.5
17.3 6.4 94.8 22.2
18.7 5.9 85.3 21.4
21 15.5 95.4 35.5
26.3 18.5 73.6 26.6
31 22 80 16.3
d mean measurements is determined by ANOVA test and Post Hoc-
lar filteration rate.
Table 5 Adverse events induced during the follow-up
period.
Adverse event N, (%)
Gastrointestinal
Diarrhea 5 (14.7)
Constipation 1 (2.9)
Abdominal pain 2 (5.9)
Viral gastritis 4 (11.8)
Bacterial gastroenteritis 3 (8.8)
Cardiovascular
Hypertension 2 (5.9)
Hypertensive encephalopathy 1 (2.9)
Chest pain 1 (2.9)
Infections
Urinary tract infection 12 (35.3)
Pyelonephritis 1 (2.9)
Respiratory infection 6 (17.7)
Sepsis 2 (5.9)
Acute otitis media 2 (5.9)
Gingivitis 1 (2.9)
Fungal
Candida 4 (11.8)
Viral 8 (23.5)
Cytomegalovirus 3 (8.8)
Herpes zoster 3 (8.8)
Herpes simplex 5 (14.7)
H. influenza 2 (5.9)
Varicella zoster 2 (5.9)
Dermatological
Skin fungal infection 3 (8.8)
Skin viral infection 5 (14.7)
Skin bacterial infection (S. aureus,
S. epidermis)
1 (2.9)
Allergic rash 1 (2.9)
Metabolic
Diabetes 5 (14.7)
Diabetic ketoacidosis 2 (5.9)
Hyperkalemia 9 (15.3)
Hypokalemia 5 (8.5)
Nephrologic
Nephrotoxicity 4 (11.8)
Hydronephrosis 2 (5.9)
Recurrence of old disease 2 (5.9)
Hematologic
Anemia 4 (11.8)
Thrombocytopenia 1 (2.9)
Leucopenia 3 (8.8)
Neurologic
Tremor 1 (2.9)
Organic psychosis 1 (2.9)
Dehydration 1 (2.9)
Visual disturbances 2 (5.9)
Lower limbs edema 1 (2.9)
Dental abscess 1 (2.9)
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outcomes.
According to previous clinical trials, retrospective anal-
ysis and longitudinal prospective follow-up studies were
conducted in pediatric renal transplant from live donors
encompassing various ethnic groups including: Amer-
ican,7,24 Canadian,1,2,38 European,3,10,14,15,25,35 South
Asian,5,6,16,20,26e28 Indian,11 Turkish,8,12,13 and Arabic9
populations. These studies reported that survival rates at
1 year, 3 years, 5 years and 10 years ranged between 92.5%
to 100%, 91% to 96.4%, 92% to 98.6%, and 71.4% to 95%,
respectively. The corresponding graft survival rates for
these studies were as follows: 82% to 100%, 78% to 90%, 67%
to 100%, and 45% to 68%, respectively. In comparison, the
findings of this study report excellent patient and graft
survival findings (of 97% and 91.2%, respectively) over
a median follow-up period of 18 months (6 months to 64
months).
Early acute rejection episodes were seen at much lower
rates in our pediatrics (14.7%) than in most previous
multinational data2,3,5,7,12,14,16,22,26,28,35,36 (25% to 54%).
Yet this finding is comparable to incidences described in
some other ethnic minorities.6,8,11,13,20,27 Interestingly, all
observed episodes in the current series, except for one,
were steroid sensitive, which was completely reversed by
methylprednisolone therapy. A possible explanation for this
finding is that all of our patients were treated with TAC,
rather than cyclosporine; the former treatment was
demonstrated to have greater efficacy in preventing acute
steroid-insensitive rejections.1,3 Another important factor
which most probably accounts for the lower acute rejection
rate in these patients is the protective effect of a living
donation, especially from many of the sampled patients’
parents. A similar impact of donor source overriding the
factor of ethnicity has been observed in African-American
and Austrian or Canadian immigrant patients receiving
kidneys from living donors; they demonstrated better
outcomes as compared with analogous groups who received
transplants from deceased donors.33,35,36
Similar to the previous experience of the Canadian and
Australian centers,36 the higher incidence of glomerulo-
nephritis as the primary etiology of ESRD among our pop-
ulation may have significantly contributed to our graft
losses. Indeed, the three patients who lost their graft in
our series had MPGN (nZ 1), RPGN (nZ 1), or celiac
disease as the main cause of their ESRD. In fact, a previous
registry study involving 1505 patients44 had reported that
recurrent glomerulonephritis was the third most frequent
cause for graft loss, where the risk of loss due to recur-
rence was estimated to increase from 0.6% in the first year
to 8.4% in the tenth year, posttransplant. Retrans-
plantation was not performed in any of our patients who
lost their graft, due to concerns of recurrence (nZ 2) or
death (nZ 1).
Preemptive transplantation has been the most preferred
treatment modality for pediatric ESRD for several reasons.
However, this preference is mainly due to a reported
favorable effect on growth and cognitive development and
avoidance of severe long-term uremic symptoms and
morbidities.45 Moreover, previous studies revealed that
preemptive transplant was associated with either more
promising46 or similar outcomes for graft survival after
Pediatric renal transplantation in Jordan 31transplantation.47 In spite of all these advantages, many
patients will require dialysis before transplantation, due to
the unavailability of a suitable donor.45
Most of our cohort has undertaken hemodialysis, peri-
toneal dialysis, or both modalities prior transplant (76.5%)
for an average of 16 months 15 months and only 23.5%
received preemptive transplantation. This frequency is in
accordance with the North American Pediatric Renal
Transplant Cooperative Study (NAPRTCS) report of 25%
transplanted preemptively.46 This could be a possible
explanation for the higher prevalence of older age (> 9
years; 82.4%) in the current transplantation report. Alter-
natively, this could be a positive factor to improve future
outcomes because both patient and graft survival rates are
higher in children over 5 years of age48.
Unexpectedly, the outcomes of our preemptive trans-
plants (23.5%) were comparable with their nonpreemptive
counterparts in terms of acute rejection (12.5% vs. 15.4%)
and patient survival (100% vs. 96.2%). However, the
frequencies of drug-related adverse events (87.5% vs.
80.8%), and particularly the new onset of diabetes (25% vs.
7.6%), were markedly higher in the preemptive transplant
recipients. Yet these results might be preliminary due to
the unequal sample sizes in the two counterparts; before
we draw conclusions, we must await further validation from
larger groups and cohorts.
In regard to graft function expressed by GFR and SrCr,
this improved drastically within the first 14 days post-
transplant and its stability was maintained throughout the
observation period. Even after three years, it sustained
higher1,2,4,10 or comparable13,49 levels with those achieved
by other populations from large centers. As noted, younger
and older age groups in our series (Figure 2) fared similarly
with respect to their improvement and stability of graft
function.
The development of posttransplant diabetes (PTD) has
mostly evolved in adults posttransplant,13,16,23,50 although
at a variable range (from 3% to 46%) and at a lower
frequency in pediatrics (between 3% and 5%). This
complication has been predominantly attributed to the
diabetogenic effect of both steroids and TAC-based immu-
nosuppressive therapy.2,4 Surprisingly, the prevalence of
PTD among our series was noted to be high (14.7%) as
compared with the NAPRTCS study23 and other pediatric
studies,2,16 although it is still comparable with some
surveys that studied diverse ethnic populations.6,20,26 A few
reports verified the onset of PTD in association with an
increased risk of acute rejection13,16,23,50 or diabetic
ketoacidosis,51 leading to subsequent graft loss. Neverthe-
less, the coincidence of these complications was only noted
in one diabetic female patient among our cohort. Another
patient experienced diabetic ketoacidosis but this patient
had preserved kidney function and graft survival. The high
prevalence of PTD in our cohort may be attributed to
a number of clinical variables suggested by previous reports
on different ethnic groups,4,18,23,34 including positive family
history, obesity, increased diabetogenic effect of TAC in
combination with MMF (vs. cyclosporine and AZA), high TAC
trough levels, and ethnicity. However, we do not yet know
which of these variables would have a quantitatively higher
and/or independent impact on increasing glucose abnor-
mality in this cohort.Hypertension, which is deemed to cause deleterious
effects on kidney functioning, remains a frequent problem
posttransplant as well2,8,10,11,15,16 (25% to 67%). In our
study, pre- and posttransplant hypertension (PTH) was
diagnosed in 82.4% and 5.9% of the patients, respectively.
About 85% of our series were either managed by one (14.7%)
or received a mean of 2.3 0.9 (70.5%; range, 2e4) anti-
hypertensive medications; the mean systolic blood pressure
(SBP)/ diastolic blood pressure (DBP) by the end of 3 years
was 122/68 mmHg ( 6.8/12.7). Again, the prevalence of
PTD and PTH were higher than previously reported inter-
national figures.2,8,10,11,15,16,23 It is important to point out
that it is imperative to resolve the latter two risk factors to
avoid further fatal and nonfatal cardiovascular events,
which are extensively reported in pediatric renal transplant
recipients,15,52e54 if these complications continue to man-
ifest.15,51e53 Actually, increased total mortality has been
mostly attributed to the stronger negative impact of
propagating cardiovascular risk factors, rather than graft
loss itself.15,51e53 Accordingly, demographic and clinical
patient variables related to their prominent incidence in
our pediatric population should be examined in future
surveys.
Despite the fact that most of our patients experienced
side effects, none of the observed effects were life
threatening. The urinary and respiratory infections that
were experienced by patients in our cohort are also
frequently reported in related studies, from 57%9 and 52%11
respectively. In our results, these infections occurred at
lower rates (38% and 17.7%, respectively). Yet again, all
cases were successfully managed. Complicated infection
with polymerase chain reaction (PCR) confirmed CMV was
described to arise at a variable range from 3.6% to 20% of
pediatric renal transplant.8,10 In our series, it was 8.8%. At
our institution, all CMV cases were efficiently controlled
with a suitable antiviral treatment protocol.
Noncompliance with immunosuppressive drugs, which is
more prevalent in children, has been described as having
a strong correlation with acute and chronic rejec-
tions.8,11,16,27 Perhaps the favorable outcomes in the
current study can be somewhat justified by the perfect
compliance of our children to immunosuppressive therapy,
which was confirmed during their clinic visits. In addition,
the patients were provided with a continuous therapeutic
drug monitoring service to maintain TAC target concentra-
tions. However, in the present paper, we have not analyzed
the impact of initial patient parameters and other
contributing biological factors that could potentially alter
the initial or ultimate TAC dosage requirements22,28,29,55;
these details remain to be tailored in our upcoming pop-
ulation pharmacokinetic modeling study.
In conclusion, despite the high prevalence of PTD and
PTH, the current pediatric renal transplant cohort within
the main Jordanian pediatric center has progressed well.
Moreover, the overall survival outcome of the cohort
compares favorably with counterparts in developed coun-
tries in respect to both efficacy and safety. Other important
issues underlying the individualization of current immuno-
suppressive therapy (TAC, steroids, or MMF) with the aim of
reducing the incidence of PTD and PTH, while still
managing to avoid compromising the survival outcomes due
to underimmunosuppression, need to be fully addressed in
32 S. Shilbayeh, I. Hazzaour future multivariate study. Less serious adverse events,
including gastrointestinal and hematological infections that
are frequent among different populations, were easier to
control. However, there is still a need for more compre-
hensive detection and care programs.References
1. Filler G, Webb NJA, Milford DV, et al. Four-year data after
pediatric renal transplantation: A randomised trial of tacroli-
mus vs. cyclosporine microemulsion. Pediatr Transplant 2005;
9:498e503.
2. Trompeter R, Filler G, Webb NJA, et al. Randomized trial of
tacrolimus versus cyclosporin microemulsion in renal trans-
plantation. Pediatr Nephrol 2002;17:141e9.
3. Hauser IA, Neumayer HN, on behalf of the European Multi-
center Tacrolimus (FK506) Renal Study Group. Tacrolimus and
cyclosporine efficacy in high-risk kidney transplantation.
Tranpl Int 1998;11:S73e7.
4. Neylan JF, for The FK506 Kidney Transplant Study Group. Racial
differences in renal transplantation after immunosuppression
with tacrolimus versus cyclosporine. Transplantation 1998;65:
515e23.
5. Chu SH, Chen Y, Chiang YJ, Chuang CK. Outcome of pediatric
renal transplantation in a single center from Taiwan. Trans-
plant Proc 2003;35:163e4.
6. Yeung S, Tsang WK, Tong KL, et al. Primary immunosuppression
with tacrolimus and low-dose mycophenolate mofetil in renal
transplant recipients. Transplant Proc 2004;36:2084e6.
7. Jordan ML, Shapiro R, Scantlebury V, et al. Tacrolimus-based
immunosuppression in pediatric renal transplantation. Trans-
plant Proc 1999;31:29e30.
8. Berber I, Tellioglu G, Yigit B, Turkmen F, Titiz MI, Altaca G.
Pediatric renal transplantation: Clinical analysis of 28 cases.
Transplant Proc 2006;38:430e1.
9. Al Baba MA, Shaheen FAM, Sheikh IA, Nivien K, Alkhader A,
Fallatah A. Experience of Jeddah Kidney Center in pediatric
renal transplantation. Tranplant Proc 1998;30:3679e80.
10. Pape L, Henne T, Strehlau J, Latta K, Ehrich JHH, Offner G.
Long-term stable glomerular filteration rate achieved with
tacrolimus in pediatric renal transplantation. Transplant Proc
2002;34:2211e2.
11. Vasudevan A, Lyengar A, Jose B, Phadke K. Pediatric renal
transplantation: a single-center experience. Transplant Proc
2008;40:1095e8.
12. Emiroglu R, Moray G, Sevmis S, Sozen MH, Bilgin N, Haberal M.
Long-term results of pediatric renal transplantation at one
center in Turkey. Transplant Proc 2005;37:675e8.
13. Duzova A, Aki T, Bakkaloglu A, et al. Triple immunosuppression
with tacrolimus in pediatric renal transplantation: Single-
center experience. Transplant Proc 2008;40:132e4.
14. Kyriakides GK, Hadjigavriel M, Nicolaidou A, Nicolaou P. Pedi-
atric renal transplants in Cyprus. Transplant Proc 1997;29:
3077.
15. Ferraris JR, Ghezzi L, Waisman G, Krmar RT. Potential
cardiovascular risk factors in paediatric renal transplant
recipients. Pediatr Nephrol 2006;21:119e25.
16. Shu H, Mu W, Youhua Z, et al. Therapeutic effectiveness of
pediatric renal transplantation in 63 cases. J Med Coll PLA
2008;23:20e5.
17. Loucaidou M, Prasad S, Van Tromp J, et al. Outcome of renal
transplantation in South Asian recipients is similar to that in
non-Asians. Transplantation 2004;78:1021e4.
18. Weber CLC, Rush DN, Jeffery JR, Cheang M, Karpinski ME.
Kidney transplantation outcomes in Canada Aboriginals. Am J
Transplant 2006;6:1875e81.19. Omoloja A, Mitsnefes M, Talley L, Benfield M, Neu A. Racial
differences in graft survival: A report from the North American
Pediatrics Renal Trials and Collaborative Studies (NAPRTCS).
Clin J Am Soc Nephrol 2007;2:524e8.
20. Yoshimura N, Oka T, Ohmori Y, et al. Combination Therapy of
tacrolimus (FK506) with azathioprine and steroids in renal
transplant recipients. Transplant Proc 1998;30:33e5.
21. Lerner GR, Warady BA, Sullivan EK, Alexander SR. Chronic
dialysis in children and adolescents. The 1996 annual report of
the North American Pediatric Renal Transplant Cooperative
Study. Pediatr Nephrol 1999;13:404e17.
22. Tejani AH, Sullivan EK, Alexander SR, Fine RN, Harmon WE,
Kohaut EC. Predictive factors for delayed graft function (DGF)
and its impact on renal graft survival in children: A report of
the North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS). Pediatr Transplant 1999;3:293e300.
23. Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes
mellitus in pediatric renal transplant recipients: a report of the
North American Pediatric Renal Transplant Cooperative Study
(NAPRTCS). Transplantation 2001;72:1020e4.
24. Avner ED, Chavers B, Sullivan K, et al. Renal transplantation
and chronic dialysis in children and adolescents: the 1993
annual report of the North American Pediatric Renal Transplant
Cooperative Study. Pediatr Nephrol 1995;9:61e73.
25. Montini G, Ujka F, Varagnolo C, et al. The pharmacokinetics
and immunosuppressive response of tacrolimus in paediatric
renal transplant recipients. Pediatr Nephrol 2006;21:719e24.
26. Hasegawa A, Oshima S, Takahashi K, Uchida K, Ito K, Sonoda T.
Successful treatment of 115 pediatric renal transplant
recipients with tacrolimus-based immunosuppression therapy:
A 7-year multicenter study in Japan. Transplant Proc 2005;37:
1769e70.
27. Iitaka K, Hojo M, Moriya S, et al. Long-term follow-up of renal
transplantation in children: A 20-year experience at one kidney
center in Japan. Clin Exp Nephrol 1997;1:273e7.
28. Ishibashi M, Miyamoto S, Nojima M, et al. Elimination of the
adverse effects of tacrolimus-based induction therapy by a 5-
day exposure of optimal steady-state blood concentration in
renal transplant patients in the early postoperative period.
Transplant Proc 1999;31:2761e2.
29. MacPhee IAM, Fredericks S, Tai T, et al. The influence of
pharmacogenetics on the time to achieve target tacrolimus
concentrations after kidney transplantation. Am J Transplant
2004;4:914e9.
30. OPTN-SRTR. Annual Report. Available at www.optn.org; 2008.
31. FillerG.Evidence-based immunosuppressionafterpediatric renal
transplantation- a dream? Transplant Proc 2003;35:2125e7.
32. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immuno-
suppression in renal transplantation: meta-analysis of
randomized trials. BMJ 1999;318:1104e7.
33. Pallet N, Thervet E, Alberti C, et al. Kidney transplant in black
recipients: are African European different from African
Americans? Am J Transplant 2005;5:2682e7.
34. Dooldeniya MD, Dupont PJ, He X, et al. Renal transplantation in
Indo-Asian patients in the UK. Am J Transplant 2006;6:761e9.
35. Oztek FZ, Ipsiroglu O, Mueller T, Aufricht C. Outcome after
renal transplantation in children from native and immigrant
families in Austria. Eur J Pediatr 2009;168:11e6.
36. Matsuda-Abedini M, Al-AlSheikh K, Hurley RM, et al. Outcome
of kidney transplantation in Canadian Aboriginal children in the
province of British Columbia. Pediatr Transplant 2009;13:
856e60.
37. Mahle WT, Kanter KR, Vincent RN. Disparities in outcome for
African-Americans following pediatric heart transplantation. J
Pediatr 2005;147:739e43.
38. Gaston RS, Benfield M. The relationship between ethnicity and
outcomes in solid organ transplantation. J Pediatr 2005;147:
721e3.
Pediatric renal transplantation in Jordan 3339. Benfield MR, McDonald RA, Bartosh S, Ho PL, Harmon W.
Changing trends in pediatric transplantation: 2001 annual
report of the North American Pediatric Renal Transplant
Cooperative Study. Pediatr Transplant 2003;7:321e35.
40. Hutching A, Benefield MR. Increased costimulatory responses in
African-American kidney allograft recipients. Transplantation
2001;71:692e5.
41. Schwartz GJ, Haycock GB, Edelmann Jr CM, Spitzer A. A simple
estimate of glomerular filteration rate in children derived from
body length and plasma creatinine. Pediatrics 1976;58:
259e63.
42. Sacca E, Hazza I. Pediatric end-stage renal disease: single center
analysis. Saudi J Kidney Dis Transplant 2006;17:581e5.
43. El Aun M, Hazza I, Qudah E, Najada AH, Khairi Y. Causes of
chronic renal failure in children in a single hospital in Jordan: A
10 years retrospective study. Saudi J Kidney Dis Transplant
1995;6:290e3.
44. Briganti EM, Russ GR, Mc Neil JJ, Atkins RC, Chabdan SJ. Risk of
renal allograft loss from recurrent glomerulonephritis. N Eng J
Med 2002;347:103e9.
45. Sacca E, Hazza I. Pre-emptive pediatric renal transplantation.
Saudi J Kidney Dis Transplant 2006;17:549e58.
46. Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant
dialysis status and outcome of renal transplantation in North
American Pediatric Renal Transplant Cooperative Study.
Transplantation 2000;69:1414e9.
47. Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT.
Preemptive kidney transplantation: the advantage and the
advantaged. J Am Soc Nephrol 2002;13:1358e64.48. Ishitani M, Isaacs R, Norwood V, Nocks S, Lobo P. Predictors of
graft survival in pediatric living-related kidney transplant
recipients. Transplantation 2000;70:288e92.
49. Neu Am, Ho PL, Fine RN, Furth SL, Fivush BA. Tacrolimus vs.
cyclosporine A as primary immunosuppression in pediatric
renal transplantation: A NAPRTCS study. Pediatr Transplant
2003;7:217e22.
50. Sharma A, Minz M, Singh S. Incidence of glucose metabolic
abnormalities in Indian living renal allograft recipients on
tacrolimus-based triple drug immunosuppression. Transplant
Proc 2008;40:2414e5.
51. Ersoy A, Ersoy C, Tekce H, Yavascaoglu I, Dilek K. Diabetic
ketoacidosis following development of De Novo diabetes in
renal transplant recipient associated with tacrolimus. Trans-
plant Proc 2004;36:1407e10.
52. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery
calcification in young adults with end-stage renal disease who
are undergoing dialysis. N Engl J Med 2000;18:1478e83.
53. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular
diseases in renal transplant recipients. Transplantation 2000;
70:S41e5.
54. Koshy SM, Guttmann A, Hebert D, Parkes RK, Logan AG. Inci-
dence and risk factors for cardiovascular events and death in
pediatric renal transplant patients: a single center long-term
outcome study. Pediatr Transplant 2009;13:1027e33.
55. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to
optimize tacrolimus therapy in solid organ transplantation:
Report of the European Consensus Conference. Ther Drug
Monit 2009;31:139e52.
